| 000 | 01299 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250518062116.0 | ||
| 264 | 0 | _c20191125 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1751-2441 | ||
| 024 | 7 |
_a10.1080/17512433.2019.1670059 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBilgic, A | |
| 245 | 0 | 0 |
_aWhat is novel in the clinical management of pemphigus. _h[electronic resource] |
| 260 |
_bExpert review of clinical pharmacology _cOct 2019 |
||
| 300 |
_a973-980 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xadministration & dosage |
| 650 | 0 | 4 |
_aAgammaglobulinaemia Tyrosine Kinase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDrug Development _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aPemphigus _xdrug therapy |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aMurrell, D F | |
| 773 | 0 |
_tExpert review of clinical pharmacology _gvol. 12 _gno. 10 _gp. 973-980 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/17512433.2019.1670059 _zAvailable from publisher's website |
| 999 |
_c30141291 _d30141291 |
||